Table 9.
Clinical versus pathological staging and interval for NAR scoring.
| Id | Arm | Baseline |
Best OR | Wks from end of NACT to surgery | Resect | ypT | ypN | Regression | NAR | Relapsed or died | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| cT stage | cN stage | MRI EMVI | ||||||||||
| 2 | 1 | T3c | N2 | Y | PR | 6·3 | R0 | ypT2 | pN1 | Good | 20·4 | NO |
| 3 | 1 | T3b | N2 | N | PR | 6·4 | R0 | ypT2 | pN0 | Minimal | 8·4 | NO |
| 6 | 1 | T3b | N2 | N | PR | 11·9 | R0 | ypT3a | pN0 | None | 15·0 | Yes |
| 7 | 1 | T3b | N0 | N | PR | Refused surgery | Yes | |||||
| 9 | 1 | T3c | N0 | Y | PR | No surgery suicide | Yes | |||||
| 11 | 1 | T3c | N0 | N | PR | 10·9 | R0 | ypT3a | pN0 | Good | 15·0 | NO |
| 14 | 1 | T3b | N1 | N | CR | 7·6 | R0 | ypT2 | pN0 | Moderate | 8·4 | NO |
| 16 | 1 | T3c | N2 | Y | PR | 6·6 | R2 | ypT4 | pN2 | Minimal | 65·0 | Yes |
| 17 | 1 | T3c | N0 | Y | PR | 22·1 | R0 | ypT2 | pN1 | Moderate | 20·4 | NO |
| 18 | 1 | T3b | N1 | Y | PR | 9·7 | R0 | ypT3a | pN2 | Minimal | 50·4 | Yes |
| 1 | 2 | T3c | N2 | Y | SD | 27·4 | R0 | ypT2 | pN1 | Moderate | 30·1 | NO |
| 4 | 2 | T3b | N1 | N | PR | 6·1 | R0 | ypT2 | pN0 | Moderate | 8·4 | NO |
| 5 | 2 | T3c | N2 | Y | PR | 7·9 | R0 | ypT3b | pN0 | Moderate | 15·0 | NO |
| 8 | 2 | T3b | N2 | N | CR | 9·4 | R0 | ypT0 | pN0 | Total | 0·9 | NO |
| 10 | 2 | T3b | N2 | Y | SD | 7·1 | R0 | ypT3c | pN0 | Minimal | 15·0 | NO |
| 12 | 2 | T4 | N1 | N | CR | 5·9 | R0 | ypT0 | pN0 | Total | 0 | NO |
| 13 | 2 | T3b | N1 | N | PR | 7·4 | R0 | ypT1 | pN0 | Moderate | 3·7 | NO |
| 15 | 2 | T3b | N1 | Y | CR | 8·7 | R0 | ypT1 | pN0 | Good | 3·7 | NO |
| 19 | 2 | T3c | N1 | N | SD | 7·4 | R0 | ypT3b | pN2 | Moderate | 50·4 | NO |
| 20 | 2 | T3d | N2 | Y | PR | 9·7 | R0 | ypT1 | pN0 | Good | 3·7 | NO |
Three patients discontinued treatment early. Patient 1 in FOLFOXIRI arm did not respond according to SUV after 3 cycles; patient 17 in the FOLFOX arm stopped treatment in cycle 1 due to myocardial infarction and patient 9 committed suicide after 4 cycles of treatment.
Arm 1 = FOLFOX plus Bevacizumab, Arm 2 = FOLFOXIRI plus Bevacizumab; cT stage = clinical Tumour stage (TNM); cN = clinical nodal stage (TNM); MR EMVI = extramural vascular invasion defined on staging MRI; OR = overall response; PR = clinical partial response; CR = clinical complete response; R0 = curative resection with margin >1 mm; ypT = pathological tumour T stage after treatment; ypN = pathological nodal stage after treatment; NAR = neoadjuvant rectal score.